Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2318 | Meditation app usage Wiki | 1.00 |
| drug2433 | Montmorrillonite Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Coronavirus disease 2019 (COVID-19) rapidly spread across China and throughout the world, causing hundreds of thousands died. Studies had shown that "cytokine storms" and subsequent multiple organ dysfunction (MODS) are important causes for disease progression and death in patients with COVID-19. Similar to SARS-CoV infection, SARS-CoV-2 would infect humans via binding of S-protein to angiotensin-converting enzyme 2 (ACE2), a host cell receptor, and the S protein is activated and cleaved by cellular transmembrane serine proteases, allowing the virus to release fusion peptides for membrane fusion. In addition to the lungs, ACE2 is also highly expressed in the esophagus, small intestine and colon, suggesting that the gut might also be an important target organ for SARS-CoV-2. About 8-16% of severe pneumonia cases confirmed with SARS-CoV-2 infection developed gastrointestinal symptoms such as abdominal pain, vomiting, and diarrhea. Moreover, the stool of patient with COVID-19 also positive by real-time reverse-transcriptase-polymerase-chain-reaction (rRT-PCR) assay. Furthermore, elevated faecal calprotectin was observed in patients with COVID-19 suggested an inflammatory response in the gut, which was significantly correlated with IL-6. For severe and critical cases, control "cytokine storms" and maintain intestinal microenvironment balance have been included into the Diagnosis and Treatment Guideline of patients with COVID-19 (Edition 7). Berberine is a quaternary ammonium alkaloid isolated from rhizoma coptidis. It is often used in treatment of infectious diarrhea by bacteriostasis and inhibition of intestinal gland secretion. Berberine has also been found to have a role in intestinal immune regulation, inhibiting both AP-1 and NF- B, the key factors in cell signal transduction, and reducing the inflammatory response. Investigators conducted a prospective randomized controlled clinical trial to investigate the effects of berberine on intestinal function, serum concentrations of the inflammatory biomarkers, and organ function in severe patients with SARS-CoV-2 infection.
Description: Including diarrhea in times/day, Bristol Stool Scale (the minimum 1 and maximum 7, a higher scores mean a worse outcome) and whether patient has any one of gastrointestinal symptoms (nausea, vomiting, abdominal pain, abdominal distension or diarrhoea).
Measure: Changes in diarrhea frequency and Bristol Stool Scale Time: daily, from date of randomization until the date of discharge or date of death from any cause, assessed up to 2 weeks.Description: evaluate inflammatory response, blood sample collected at 6:00am
Measure: IL-6 (ng/ml) Time: baseline (at admission), day 3,7 and14 after admission or until the date of discharge or date of death from any causeDescription: evaluate inflammatory response, blood sample collected at 6:00am
Measure: IL-10（ng/ml） Time: baseline (at admission), day 3,7 and14 after admission or until the date of discharge or date of death from any causeDescription: evaluate inflammatory response, blood sample collected at 6:00am
Measure: IL-1β (ng/ml) Time: baseline (at admission), day 3,7 and14 after admission or until the date of discharge or date of death from any causeDescription: evaluate inflammatory response, blood sample collected at 6:00am
Measure: TNF-α (pg/ml) Time: baseline (at admission), day 3,7 and14 after admission or until the date of discharge or date of death from any causeDescription: evaluate inflammatory response, blood sample collected at 6:00am
Measure: leukocyte count (10^9/l) Time: baseline (at admission), day 3,7 and14 after admission or until the date of discharge or date of death from any causeDescription: evaluate inflammatory response, blood sample collected at 6:00am
Measure: c reactive protein (mg/l) Time: baseline (at admission), day 3,7 and14 after admission or until the date of discharge or date of death from any causeDescription: evaluate inflammatory response, blood sample collected at 6:00am
Measure: procalcitonin (ng/ml) Time: baseline (at admission), day 3,7 and14 after admission or until the date of discharge or date of death from any causeDescription: evaluate the severity of the disease(the minimum 0 and maximum 24, a higher scores mean a worse outcome)
Measure: Sequential Organ Failure Assessment (SOFA) score Time: baseline (at admission), day 3, 7 and 14 after admission or until the date of discharge or date of death from any causeAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports